ALK and GenSci partner to expand the AIT market in China
Inside Information GenSci is granted exclusive rights to ALK’s house dust mite…
EURneffy approved as the first needle-free anaphylaxis treatment of adults and children in the UK
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the…
First market launch of the adrenaline nasal spray, EURneffy, for treatment of adults and children in Germany
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch…
